Kewalramani Reshma 4

What happened

Reshma Kewalramani, CEO & President and a director of Vertex Pharmaceuticals (VRTX), was reported as acquiring two awards on 2026-01-22 that total 38,857 shares (26,972 + 11,885). The Form 4 shows an acquisition price of $0.00 for both items (these are earned performance shares resulting from previously granted performance stock unit awards). The shares will vest in February 2026 per the issuer’s certification of performance goals.

Key details

• Transaction date: 2026-01-22 (Form 4 filed 2026-01-26 — timely filing).
• Type/code: A = Award/Grant (performance-based stock units converted to earned shares).
• Share amounts and price: 26,972 shares @ $0.00 (footnote F1) and 11,885 shares @ $0.00 (footnote F2); total 38,857 shares.
• Vesting: F1 shares vest on 02/13/2026; F2 shares vest in installments beginning 02/24/2026, after the committee certified performance on 01/22/2026.
• Shares owned after transaction: Not specified in the Form 4.
• Filing timeliness: Filed within expected window (transaction 01/22, filed 01/26).

Context

These are performance-vested equity awards (not open-market purchases or sales). An acquisition price of $0 reflects conversion of earned performance units into shares upon certification of performance goals; the shares become fully owned only as they vest. Such awards are routine elements of executive compensation tied to long-term performance and do not, by themselves, indicate a personal cash investment or immediate market sentiment.